
Loading, please wait...

Loading, please wait...

Meropenem extended infusion stability has long been a challenge for critical care and infectious disease specialists. While traditional package inserts limit room-temperature stability to just one hour, clinical practice often requires longer windows for optimized drug delivery. Recent evidence now confirms that meropenem remains stable for significantly longer periods when diluted in normal saline.
Researchers recently evaluated the chemical stability of meropenem (1 g) diluted in 100 mL of 0.9% sodium chloride (NS). They stored the solutions at controlled room temperatures between 23-25 °C and used high-performance liquid chromatography (HPLC) to measure degradation. The study found that meropenem maintained over 90% of its initial concentration for up to 12 hours. However, by the 24-hour mark, the concentration fell to approximately 86.65%, which is below the acceptable threshold.
This extended stability window has profound implications for antimicrobial stewardship. Meropenem is a time-dependent antibiotic, meaning its efficacy depends on the duration that the free drug concentration remains above the Minimum Inhibitory Concentration (MIC). Consequently, prolonged infusions are the gold standard for treating severe infections. Furthermore, a 12-hour stability period simplifies nursing workflows and pharmacy compounding, as it removes the need for immediate, high-pressure administration. Clinicians should note that these findings specifically apply to polyvinyl chloride bags and normal saline diluents. Therefore, switching to dextrose or higher temperatures may still compromise drug integrity.
Meropenem is highly sensitive to heat. While it remains stable for 12 hours at 23-25 °C, stability drops significantly at higher temperatures (e.g., above 30 °C), which is a common concern in warmer clinical environments without climate control.
Studies consistently show that meropenem degrades much faster in dextrose-based solutions. For extended or continuous infusions, 0.9% sodium chloride is the mandatory diluent to ensure the drug remains therapeutically active.
Yes, higher concentrations of meropenem tend to degrade more rapidly. The 12-hour stability finding is specific to a concentration of approximately 10-13 mg/mL in a 100 mL bag.
Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
1. Howington GT et al. Extended stability of meropenem in 0.9% sodium chloride injection stored at 23-25 °C. Am J Health Syst Pharm. 2026 Apr 04. doi: undefined. PMID: 41935840.
2. Mollá-Cantavella S et al. Intravenous meropenem stability in physiological saline at room temperature. Eur J Hosp Pharm. 2014;21:A128.
3. Yu Z et al. Clinical outcomes of prolonged infusion versus intermittent bolus of meropenem in severe infection: A meta-analysis. PLoS One. 2018;13(7):e0201667.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A new study demonstrates that meropenem in 0.9% sodium chloride is stable for up to 12 hours at room temperature, enabling more effective extended infusions...
5 months ago

A large NHANES cohort study reveals that higher Healthy Eating Index scores significantly reduce all-cause mortality risk in CKD patients by 45%. This analysis highlights the importance of comprehensive diet quality and medical nutrition therapy in renal care to optimize long-term clinical survival.
Today

A prospective cohort study demonstrates that poor adolescent sleep quality, especially long sleep latency and reduced efficiency, increases dysmenorrhea severity in young adulthood. Addressing adolescent rest patterns offers a critical preventive avenue for clinicians.
Today

A meta-analysis of 13 propensity score-matched studies shows ViV-TAVR delivers lower early mortality and reduced bleeding compared to redo-SAVR for degenerated bioprosthetic aortic valves, though long-term hemodynamics warrant careful anatomical and patient-centered evaluation.
Today

Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Today

The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today